Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Yes that observe1 cost me alot - only listen to yourself not to say john called it good 10.60 and myself 10.77 dumped 10k - bought 1k 9.55 1k 9.19 1k 8.70 - 7k more to buy lets see
go 1k 8.70euros now - best buy in 1k lots IR
I got talking to Roderick McIllree - all he can say is no news is good news!
Bought another 1k 9.19euros. JH - Are you still in AIB? I bought some can see it going over 4euros again and this over 10euros so no panic - We are full off cash . Silicon Valley Bank Chief Executive Officer Greg Becker sold $3.6 million worth of shares in his bank last week, its a one off bad management
Iron Ore Co Australia has also finalised its heritage agreement with the Karlka Nyiyaparli Aboriginal Corp, the Native Title representative group for the Nyiyaparli People. It is now progressing heritage survey works alongside agreement negotiations, and expects these to be completed in the fourth quarter of 2022.
14p springs out
Feel very good news is imminent -
Who is michael kelly ?
Done a FBS trade 1k 9.55euros - Davy`s target will go up over 13euros agree john ?
I see a very big deal coming - you do not go to all the effort for diddly-squat !
Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001.
The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors for the treatment of “cytokine storm”, including hypercytokinaemia that occurs because of a viral infection, cancer or autoimmune response by reducing the body’s hyperinflammatory response.
POLB 001 is a viral strain agnostic, small molecule immunomodulator being developed to address severe influenza and other acute inflammatory conditions. The treatment differs from other approaches, such as steroids, which can affect both beneficial and damaging immune responses. It is also unaffected by seasonal variants, giving it an advantage over other treatments on the market, and is a shelf-stable oral drug.
“We are expanding our IP portfolio across the globe, allowing us to continue advancing and protecting our programmes for the treatment or prevention of severe influenza and hypercytokinaemia,” said Poolbeg chief execuitve Jeremy Skillington. “Enhanced IP protection of our assets across key markets, such as the US, increases the overall value and attractiveness of these products to potential partners.”
Thanks john. Target 11.47euros sounds right
Any news?
Good to see a fairly positive post from you happyhaddock. Cannot not see this under 0.50 for long something brewing!
We all agree the share price is extremely boring to look at - should be 1p no less
We need to get cash rich - more deals for certain rod is the man. He might even buy more lets see
Hi Playcards - Next week over 11euros for certain - JH - Hold firm 2023 great year
Few Licensing deals first get the share price near 20p
Hi HULD!!!!!!!!!!!!!!!!!!!! - I bought first because of the Iron Ore max was on the back foot so thank me! Historic JORC 2004 compliant resource of 24Mt @ 2.9g/t PGM and Gold for 1.14Moz Pd, 0.83Moz Pt, 152Koz Au and 76Koz Rh (Rhodium)
First time in 30 years that Munni Munni and Elizabeth Hill projects have been consolidated into a single coherent tenement, under 100% ownership we have this as massive back up
Potential for a much larger, high value, multi-commodity resource many of which appear on critical mineral lists
One of the largest undeveloped primary PGM Resources in Australia.
Bill use to work for RIO